Pilot study: Fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer

Doron Gothelf, Maly Rubinstein, Eyal Shemesh, Orit Miller, Ilana Farbstein, Anat Klein, Abraham Weizman, Alan Apter, Isaac Yaniv

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Objective: To evaluate the safety, tolerability, and benefit of fluvoxamine for the treatment of major depressive disorder or anxiety disorders in children and adolescents with cancer. Method: The study was conducted from 2001 to 2004 at a pediatric hematology-oncology center. Fifteen children and adolescents with cancer were treated with fluvoxamine 100 mg/day in an open prospective 8-week trial. Safety and tolerability were evaluated at baseline and at weeks 4 and 8 by blood tests and the Side Effects Checklist. Clinical benefit was assessed with the Clinical Global Impressions-Improvement, the Children's Depression Rating Scale-Revised, and the Pediatric Anxiety Rating Scale. Results: Fluvoxamine was well tolerated by all subjects. Psychiatric symptoms improved significantly. Conclusions: In this open trial, fluvoxamine appeared to be well tolerated and was associated with a promising reduction in the depression and anxiety symptoms of pediatric patients with cancer.

Original languageEnglish
Pages (from-to)1258-1262
Number of pages5
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume44
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Keywords

  • Antidepressants
  • Cancer
  • Depression
  • Fluvoxamine

Fingerprint

Dive into the research topics of 'Pilot study: Fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer'. Together they form a unique fingerprint.

Cite this